Renal Calculi, Ureteral Obstruction
Conditions
Keywords
urolithiasis, ureteral stent, triclosan, drug eluting
Brief summary
The purpose of this study is to determine the clinical effects of a triclosan stent on adherent bacteria, stent biofilms, and patient urine cultures in patients with an indwelling triclosan ureteral stent. The patient populations that will be tested include: patients following ureteroscopy and patients scheduled to undergo shockwave lithotripsy who require a ureteral stent. It is hypothesized that triclosan eluting ureteral stents will reduce the number of bacteria both on (within biofilm) and around (in the urine) a ureteral stent.
Interventions
DEVICEUreteral Stent
triclosan-eluting ureteral stent
Sponsors
Boston Scientific Corporation
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who undergo ureteroscopy for any reason and require a ureteral stent post-operatively as determined by the surgeon (e.g. renal obstruction, ureteral edema, ureteral perforation, large stone fragments to pass, following ureteral dilation, ureteral trauma, solitary kidney, or any other reason left to the discretion of the surgeon). * Patients undergoing extracorporeal shockwave lithotripsy (ESWL) who will require a stent as determined by the treating urologist (e.g. solitary kidney, ureteral stone \> 1 cm, renal stone \> 1.5 cm, significant renal obstruction, history of pyelonephritis, or any other reason left to the discretion of the surgeon). * Patients who have or are going to have chronic ureteral stents, for any reason. * Patients willing to return to St. Joseph's Hospital's Urology Clinic for follow-up.
Exclusion criteria
* Age ≤ 17 years * Patients unable to consent. * Any patient requiring endocarditis or prosthetic device prophylaxis (e.g. fresh arthroplasty etc.). * Pregnant females * Immunocompromised patients * Significant urinary symptoms (urgency, dysuria, strangury, hematuria) or other bladder pathology that may cause these symptoms (e.g. interstitial cystitis) * Anyone in the investigator's opinion that would be unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective is to determine if the number of stent adherent bacteria will be less in patients who receive a triclosan stent compared to a control/standard stent. | at time of intervention |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives to be assessed include the amount of biofilm adherent to each stent and each patient's urine culture. | at time of intervention |
Countries
Canada
Outcome results
None listed